Cargando…
Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report
Paxlovid has shown the potential decreasing the hospitalization rate of mild or moderate coronavirus disease 2019 (COVID-19) and death in few of clinical trials, and is expected to the most promising medicine targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SRAS-COV-2). However, there are...
Autores principales: | Zhang, Liulu, Zhang, Shasha, Han, Jing, Yi, Yile, Zhou, Hourong, Li, Jianquan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665888/ https://www.ncbi.nlm.nih.gov/pubmed/36397388 http://dx.doi.org/10.1097/MD.0000000000031361 |
Ejemplares similares
-
Covid-19 vaccine effectiveness during Omicron BA.2 pandemic in Shanghai: A cross-sectional study based on EMR
por: Xu, Site, et al.
Publicado: (2022) -
Course and clinical severity of the SARS-CoV-2 Omicron variant infection in Tianjin, China
por: Ren, Yi, et al.
Publicado: (2023) -
Association of metabolic syndrome and its components with all-cause and cardiovascular mortality in the elderly: A meta-analysis of prospective cohort studies
por: Ju, Sang-Yhun, et al.
Publicado: (2017) -
Low Systolic Blood Pressure and Mortality From All-Cause and Vascular Diseases Among the Rural Elderly in Korea; Kangwha Cohort Study
por: Yi, Sang-Wook, et al.
Publicado: (2015) -
The effects of dimethylformamide exposure on liver and kidney function in the elderly population: A cross-sectional study
por: Hu, Zhi-Yong, et al.
Publicado: (2020)